Ch 9: CASH FLOWS — V2: Applied Practical Scenarios & Financial Computations
CS Executive
📚 Corporate Accounting & Financial Management
📖 Ch.9 — CASH FLOWS
📘 V2: Study Material & Test Yourself
⚡ Free Mode (Answers Locked)
⏱ Duration: 90 Mins
🎯 Total Marks: 50
Passed at: 20 Marks
Max Attempts: 10
⚖️ Statutory Applicability: Applicable for ICSI CS Executive Examinations (December 2026 Attempt - Syllabus 2022)
Exhaustive ICSI CS Executive Test Series with 4-Tier Rubrics, Statutory Analysis, and Real-world Corporate Problem Scenarios.
📑 Exam Questions
5 Questions • Total 50 MarksQuestion 1: PRACTICAL NUMERICAL: Preparation of Cash Flow Statement under AS 3 / Ind AS 7: Cash Flow from Operating Activities (Indirect Method).
10 Marks
📌 Applicable as per revised AS 3 and Ind AS 7 guidelines issued by the Ministry of Corporate Affairs (MCA), Government of India.
From the following summarized Balance Sheets of M/s Vanguard Agro-Industries Ltd. as at 31st March 2024 and 31st March 2023, along with the Statement of Profit and Loss for the year ended 31st March 2024 and additional information, you are required to compute the Cash Flow from Operating Activities using the Indirect Method in accordance with Accounting Standard 3 (AS 3) / Ind AS 7.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 2: PRACTICAL NUMERICAL: Adjustments for non-cash expenses (depreciation, amortization), profit/loss on sale of fixed assets, working capital changes.
10 Marks
📌 Companies (Accounting Standards) Rules, read with Ind AS 7 / AS 3 mandates indirect method adjustments for non-cash items and working capital variations in operating cash flows.
M/s Kalinga Pharma Limited presents its comparative Balance Sheet as at 31st March 2023 and 31st March 2024, along with additional financial information from its Statement of Profit and Loss for the year ended 31st March 2024. You are required to prepare a Cash Flow Statement from Operating Activities in accordance with Ind AS 7 / AS 3 (Cash Flow Statements) incorporating all necessary adjustments for non-cash expenses, profit/loss on sale of fixed assets, and working capital changes.
Table 1: Balance Sheet Extracts of M/s Kalinga Pharma Limited
| Particulars | Note No. | As at 31-03-2024 (₹ in Lakhs) | As at 31-03-2023 (₹ in Lakhs) |
|---|---|---|---|
| I. EQUITY AND LIABILITIES | | | |
| (1) Shareholder's Funds | | | |
| (a) Share Capital | 1 | 5,000 | 4,000 |
| (b) Reserves and Surplus (Statement of P&L Balance) | 2 | 2,850 | 1,600 |
| (2) Non-Current Liabilities | | | |
| (a) Long-term Borrowings (10% Debentures) | 3 | 2,000 | 2,500 |
| (3) Current Liabilities | | | |
| (a) Trade Payables | 4 | 1,200 | 900 |
| (b) Short-term Provisions (Provision for Tax) | 5 | 450 | 350 |
| (c) Short-term Borrowings (Bank Overdraft) | 6 | 150 | 200 |
| TOTAL | | **11,650** | **9,550** |
| II. ASSETS | | | |
| (1) Non-Current Assets | | | |
| (a) Property, Plant and Equipment (Tangible Assets) | 7 | 6,500 | 5,200 |
| (b) Intangible Assets (Goodwill / Patents written off) | 8 | 400 | 600 |
| (2) Current Assets | | | |
| (a) Inventories | 9 | 1,800 | 1,400 |
| (b) Trade Receivables | 10 | 2,100 | 1,500 |
| (c) Cash and Cash Equivalents | 11 | 850 | 350 |
| TOTAL | | **11,650** | **9,550** |
Table 2: Additional Information / Notes to Accounts
| Item Code | Particulars | Details / Financial Transactions during 2023-24 |
|---|---|---|
| A1 | Depreciation & Amortization | Depreciation charged on Property, Plant and Equipment for the year was ₹650 Lakhs. Patents amortized amounted to ₹200 Lakhs. |
| A2 | Sale of Fixed Assets | A machine costing ₹400 Lakhs (Accumulated Depreciation thereon ₹150 Lakhs) was sold during the year for ₹280 Lakhs. |
| A3 | Taxation | Income tax paid during the year amounted to ₹380 Lakhs. Provision for tax made during the current year is ₹480 Lakhs. |
| A4 | Dividend & Interest | Proposed dividend of ₹500 Lakhs was declared and paid during the year. 10% Debenture interest of ₹225 Lakhs was paid (Debentures of ₹500 Lakhs were redeemed on 01-10-2023). |
| A5 | Non-Cash Issue | Equity shares of ₹1,000 Lakhs were issued against the purchase of specialized machinery. |
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 3: PRACTICAL NUMERICAL: Cash Flow from Investing Activities (purchase/sale of assets, interest/dividend received) and Financing Activities (shares/debentures issued, dividend paid).
10 Marks
📌 Applicable provisions of Companies Act, 2013 and Accounting Standard 3 (AS-3) / Ind AS 7 on Cash Flow Statements.
From the following extracts of Balance Sheet and additional information of M/s Vanguard Technologies Limited as at 31st March 2024, prepare the Cash Flow Statement specifically focusing on Cash Flow from Investing Activities and Cash Flow from Financing Activities in accordance with Accounting Standard-3 (AS-3 / Ind AS 7).
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 4: Comprehensive review of key exam provisions of CASH FLOWS (Part 4)
10 Marks
📌 Prepared strictly in compliance with Ind AS 7 (Statement of Cash Flows) and AS-3 (Revised), incorporating rigorous adjustments for non-cash items, taxation, and classification of interest and dividends.
M/s Kalinga Pharma Ltd. provides you with the Balance Sheets as at 31st March, 2024 and 31st March, 2023, along with additional financial information. You are required to prepare a Cash Flow Statement in accordance with Ind AS 7 / AS-3 (Revised) using the Indirect Method, supported by exhaustive working notes and tabular schedules.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 5: Comprehensive review of key exam provisions of CASH FLOWS (Part 5)
10 Marks
📌 Strict adherence to AS 3 (Revised) regarding classification of interest, dividends, tax, and non-cash operating adjustments.
M/s Kalinga Pharma Ltd. presents its comparative Balance Sheets as at March 31, 2023, and March 31, 2024, along with additional information from the Statement of Profit and Loss for the year ended March 31, 2024. You are required to prepare a Cash Flow Statement in accordance with Accounting Standard (AS) 3 (Revised) using the Indirect Method, incorporating all necessary adjustments for non-cash and non-operating items, changes in working capital, taxation, and investing/financing activities.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Advertisement